title: Regulation of non-pregnant human uterine contractility. Effect of antihormones.
abstract: Uterine contractility was recorded on cycle day LH+6 to LH+8 in a control and treatment cycle in 14 healthy non-pregnant volunteers. In the treatment cycle the subjects received either 50 mg of the antiprogestin RU 486 daily for three days or 40 mg of the anti-estrogen tamoxifen daily for two days. The treatment started on day LH+2. During the recording, 2 to 5 micrograms PGF2 alpha was administered into the uterine cavity. The plasma levels of progesterone and estrogen were the same in both the control and treatment cycles. RU 486 caused a significant increase in uterine contractility expressed in Montevideo Units (MU) and a decrease in uterine tonus in comparison with corresponding data obtained in the control cycle. Following treatment with tamoxifen, uterine contractility was lower but the difference was not significant. PGF2 alpha invariably caused a stimulation of uterine contractility. However, treatment with the antihormones did not influence the response. The result of the present study indicates that the change in uterine contractility occurring in the latter part of the menstrual cycle and during menstruation is due to progesterone withdrawal.
authors.affiliation: Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Gemzell
authors.forename: M L
authors.initials: ML
authors.lastname: Swahn
authors.forename: M
authors.initials: M
authors.lastname: Bygdeman
mesh_terms: D000328:Adult; D015237:Dinoprost / Q000494:pharmacology; D005260:Female; D006801:Humans; D008183:Luteal Phase; D015735:Mifepristone / Q000494:pharmacology*; D013629:Tamoxifen / Q000494:pharmacology*; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D013629:Tamoxifen; D015735:Mifepristone; D015237:Dinoprost